Aegis Maintains Buy on Cubist (CBST) Following Q3 Results; Still Sees Pipeline Catalysts
Tweet Send to a Friend
Aegis Capital is reiterating its Buy rating and $70 price target on Cubist Pharmaceuticals Inc. (Nasdaq: CBST) following fiscal Q313 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
